Prevalence of kidney failure treatment is skyrocketing worldwide

November 07, 2013

Atlanta, GA (November 7, 2013)--The prevalence of dialysis therapy for kidney failure is increasing much faster than population growth in most parts of the world, according to a new study. The findings, which will be presented at ASN Kidney Week 2013 November 5-10 at the Georgia World Congress Center in Atlanta, GA, highlight the importance of early detection and treatment of kidney disease.

Various chronic diseases have detrimental effects on the kidneys. Rapidly rising global rates of chronic diseases portend a consequent rise in kidney failure--or end stage renal disease (ESRD)--but the change in global burden of treated ESRD has never before been quantified.

To accurately report the trajectory of treated ESRD rates at the global and regional level between 1990 and 2010, Bernadette Thomas, MD (University of Washington, in Seattle) and her colleagues examined data from the Global Burden of Disease database, the largest existing database for global causes of illness and death. They also analyzed data from national and regional ESRD registries and performed a literature review of studies from 1990 and 2010. Data from 26 countries that lack routine access to dialysis were excluded. Data from 23 countries providing 100% dialysis access and 138 countries providing partial dialysis access were included.

Among the major findings: The findings indicate that the significant growth in dialysis therapy is strikingly out of proportion to population growth for a majority of regions in the world. "This emphasizes the need for early chronic kidney disease detection and treatment targeting ESRD prevention, since continued rise in prevalence of maintenance dialysis may not be sustainable," the investigators wrote.
HighlightStudy: "The Rapidly Growing Global Burden of End-Stage Renal Disease - An Analysis of the Change in Maintenance Dialysis Prevalence between 1990 and 2010" (Abstract 4163)

Disclosures: Rajnish Mehrotra is an ad hoc consultant for Baxter Healthcare, Novartis, Shire, Johnson & Johnson; receives research funding from DaVita; and honoraria from Amgen, Baxter, DaVita, Shire, Takeda, and Vifor. Jonathan Himmelfarb is a consultant for and receives honoraria from Ardea Biosciences, Thrasos Innovations, Abbott, Affymax, Xenon; has an ownership interest in Thrasos; and receives research funding from POM Wonderful, Bristol Myers Squibb.

ASN Kidney Week 2013, the largest nephrology meeting of its kind, will provide a forum for 14,000 professionals to discuss the latest findings in renal research and engage in educational sessions related to advances in the care of patients with kidney and related disorders. Kidney Week 2013 will take place November 5-10, 2013 in Atlanta, GA.

The content of this article does not reflect the views or opinions of The American Society of Nephrology (ASN). Responsibility for the information and views expressed therein lies entirely with the author(s). ASN does not offer medical advice. All content in ASN publications is for informational purposes only, and is not intended to cover all possible uses, directions, precautions, drug interactions, or adverse effects. This content should not be used during a medical emergency or for the diagnosis or treatment of any medical condition. Please consult your doctor or other qualified health care provider if you have any questions about a medical condition, or before taking any drug, changing your diet or commencing or discontinuing any course of treatment. Do not ignore or delay obtaining professional medical advice because of information accessed through ASN. Call 911 or your doctor for all medical emergencies.

Founded in 1966, and with more than 14,000 members, the American Society of Nephrology (ASN) leads the fight against kidney disease by educating health professionals, sharing new knowledge, advancing research, and advocating the highest quality care for patients.

American Society of Nephrology

Related Dialysis Articles from Brightsurf:

Immediate dialysis no better than wait-until-necessary approach, researchers find
In the largest international study of its kind, researchers at the University of Alberta and Toronto's St.

Predictors of 5-year mortality in young dialysis patients
The analysis published in NDT [1] evaluated for the first time the association of a large number of demographic, HD treatment and laboratory variables with mortality in patients on chronic hemodialysis treatment since childhood.

COVID-19 mortality alarmingly high in dialysis patients
Analysis of a Spanish experience shows that COVID-19 is frequent in hemodialysis patients, who appear to be at risk for worse outcome.

Survival following switch from urgent in-center hemodialysis to home dialysis
Few patients who start urgent and unplanned dialysis in clinical centers switch to home dialysis.

Is ownership of dialysis facilities associated with access to kidney transplants?
An analysis that included data for nearly 1.5 million patients with end-stage kidney disease looked at whether ownership of dialysis facilities was associated with patients' access to kidney transplants.

At-home dialysis improves quality of life
The rate of people starting voluntary at-home peritoneal dialysis rose from 15% to 34% over 10 years at Kaiser Permanente in Northern California, providing a convenient and safe way to manage advanced-stage kidney disease compared with center-based hemodialysis, according to research published today in JAMA Internal Medicine.

Hydration sensor could improve dialysis
Researchers from MIT and Massachusetts General Hospital have now developed a portable sensor that can accurately measure patients' hydration levels using a technique known as nuclear magnetic resonance (NMR) relaxometry.

Uncovering possible role of polyphosphate in dialysis-related amyloidosis
Researchers from Osaka University found that the low concentrations of the naturally occurring biopolymer, polyphosphate (polyP), induces amyloid formation from β2 microglobulin under both acidic and neutral conditions but by different mechanisms.

Study compares dialysis reimbursement around the globe
Dialysis reimbursement policies in most countries are focused on conventional in-center hemodialysis, although home hemodialysis and peritoneal dialysis might contribute to quality of life and cost savings.

Elderly patients on dialysis have a high risk of dementia
Older kidney disease patients who are sick enough to require the blood-filtering treatment known as dialysis are at high risk of dementia, including Alzheimer's disease, according to a study led by scientists at Johns Hopkins Bloomberg School of Public Health.

Read More: Dialysis News and Dialysis Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to